
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ranpirnase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Orgenesis
Deal Size : $19.0 million
Deal Type : Acquisition
Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform
Details : Orgenesis and TamirBio plan to combine ranpirnase with Bioxomes, which have shown the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to natural exosomes.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
April 14, 2020
Lead Product(s) : Ranpirnase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Orgenesis
Deal Size : $19.0 million
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ranpirnase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Details : Ranpirnase is a Enzyme drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Condylomata Acuminata.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 28, 2015
Lead Product(s) : Ranpirnase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Ranpirnase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 18, 2010

 Reset All
Reset All